PTGX Protagonist Therapeutics PE ratio, current and historical analysis
As at Mar 7, 2025, the PTGX stock has a PE ratio of 8.58. This is based on the current EPS of $4.47 and the stock price of $38.35 per share. A decrease of 27% has been seen in the P/E ratio compared to the average of 11.8 of the last 4 quarters.
PTGX PE ratio history
The mean historical PE ratio of Protagonist Therapeutics over the last eight years is 20.12. The current 8.58 PE ratio is 57% below the historical average. Over the past eight years, PTGX's PE ratio was at its highest in the Jun 2017 quarter at 51.41, with a price of $11.31 and an EPS of $0.22. The Dec 2024 quarter recorded the bottom point at 8.64, with a price of $38.6 and an EPS of $4.47.
Protagonist Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | 8.64 | N/A | $38.6 | $4.47 |
| 2023 | N/A | N/A | $22.93 | -$1.39 |
| 2022 | N/A | N/A | $10.91 | -$2.6 |
| 2021 | N/A | N/A | $34.2 | -$2.71 |
| 2020 | N/A | N/A | $20.16 | -$1.92 |
| 2019 | N/A | N/A | $7.05 | -$2.98 |
| 2018 | N/A | N/A | $6.73 | -$1.74 |
| 2017 | N/A | N/A | $20.8 | -$2.09 |
| 2016 | N/A | N/A | $21.99 | -$5.8 |
| 2015 | N/A | N/A | N/A | -$59.32 |
| 2014 | N/A | N/A | N/A | -$49.38 |
Protagonist Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | 8.64 | -44.51% | $38.6 | $4.47 |
| Sep 2024 | 15.57 | 28.04% | $45 | $2.89 |
| Jun 2024 | 12.16 | 12.18% | $34.65 | $2.85 |
| Mar 2024 | 10.84 | N/A | $28.93 | $2.67 |
| Dec 2023 | N/A | N/A | $22.93 | -$1.39 |
| Sep 2023 | N/A | N/A | $16.68 | -$2.63 |
| Jun 2023 | N/A | N/A | $27.62 | -$2.69 |
| Mar 2023 | N/A | N/A | $23 | -$2.85 |
| Dec 2022 | N/A | N/A | $10.91 | -$2.6 |
| Sep 2022 | N/A | N/A | $8.43 | -$2.68 |
| Jun 2022 | N/A | N/A | $7.91 | -$2.74 |
| Mar 2022 | N/A | N/A | $23.68 | -$2.59 |
| Dec 2021 | N/A | N/A | $34.2 | -$2.71 |
| Sep 2021 | N/A | N/A | $17.72 | -$2.4 |
| Jun 2021 | N/A | N/A | $44.88 | -$1.91 |
PTGX average PE ratio chart
PTGX PE vs peers
Compared to its peer stock ORMP, PTGX's PE ratio stands lower.
| Stock name | PE ratio | Market cap |
|---|---|---|
| PTGX Protagonist Therapeutics Inc | 8.58 | $2.35B |
| ORMP Oramed Pharmaceuticals Inc | 23.36 | $103.6M |
| OLMA Olema Pharmaceuticals Inc | N/A | $264.14M |
| OMER Omeros Corp | N/A | $443.9M |
| ONVO Organovo Holdings Inc | N/A | $7.86M |
| ORIC Oric Pharmaceuticals Inc | N/A | $568.21M |
Frequently asked questions
What is Protagonist Therapeutics's PE ratio?
The price to earnings ratio for PTGX stock is 8.58 as of Mar 7, 2025.
What is the highest PE ratio for PTGX?
The highest quarterly PE ratio in the last eight years has been 51.41 and it was in the Jun 2017 quarter.
How does the current PE ratio for PTGX compare to its historical average?
PTGX's current price to earnings ratio is 57% below its 8-year historical average.
Why is Protagonist Therapeutics's PE ratio so low?
PTGX's PE ratio is low because its earnings per share (EPS) is high relative to its stock price.
How is PTGX's PE ratio calculated (Protagonist Therapeutics PE ratio formula)?
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (Mar 7, 2025), Protagonist Therapeutics's stock price is $38.35. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $4.47. Therefore, Protagonist Therapeutics's P/E ratio for today is 8.58. PE RATIO(8.58) = STOCK PRICE($38.35) / TTM EPS($4.47)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.